Brief: CytRx says announced interim analysis from two ongoing phase 1b Aldoxorubicin combination studies

LadRx

04/05/2015 14:04

May 4 (Reuters) - CytRx Corp  CYTR.O : 
 * Says announced an interim analysis from its two ongoing phase 1b 
   aldoxorubicin combination studies 
 * Says the combinations appear to be well tolerated 
 * Says company expects to complete dose escalation in this trial in the second 
   half of 2015 
 * Says aldoxorubicin demonstrates both tumor shrinkage and improved quality of 
   life in chemotherapy resistant cancers 
 * Source text for Eikon  ID:nPn6mFx2C  
 * Further company coverage  CYTR.O   
 
 ((Bengaluru Newsroom; +1 646 223 8780))